ClinicalTrials.gg
RecruitingNCT07540650pRevenTUpdated Oct 9, 2026

Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers

A Phase 2 interventional study of Prophylactic External Beam Radiotherapy and Standard of Care in Bone Metastases and Metastatic Solid Tumor, sponsored by Institute of Oncology Ljubljana. Recruiting at 1 site in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Institute of Oncology Ljubljana · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Neoplasm Metastasis with a site in Slovenia — 3 open to participants now, 4 under way, 1 of them phase 3. Neoplasm Metastasis · Slovenia.

Planned enrollment
10th of 13
90 · median 233
Started
2026
the only one that year
Phase 2
7 of 15
1 open now
Registered
15th of 15
by date
Lead sponsor
3 of 15
Institute of Oncology Ljubljana

Among the 15 studies in Neoplasm Metastasis with a site in Slovenia, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 2, and was the 15th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

3 of the 15 studies in Neoplasm Metastasis with a site in Slovenia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Slovenia have not opened yet or have stopped. Only those recruiting at a site in Slovenia →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Neoplasm Metastasis with a site in Slovenia, or all of them as a file.
02

Study summary

This is a prospective, randomized, single-center clinical trial evaluating whether early prophylactic radiotherapy to high-risk asymptomatic or minimally symptomatic bone metastases reduces the 1-year rate of skeletal-related events (SREs) in patients with metastatic solid cancers. Patients will be randomized in a 1:1 ratio to receive either standard of care systemic therapy or observation, or prophylactic radiotherapy in addition to standard of care. The primary endpoint is the 1-year rate of SREs. Secondary endpoints include adverse events, quality of life, economic burden, pain-free survival, and overall survival.

Read the detailed description

Bone metastases are a common complication in patients with metastatic solid cancers and are associated with significant morbidity, including skeletal-related events (SREs) such as pathological fractures, spinal cord compression, and severe pain requiring intervention. While palliative radiotherapy is an established treatment for symptomatic bone metastases, the role of prophylactic radiotherapy in asymptomatic or minimally symptomatic high-risk lesions remains insufficiently defined.

This prospective, randomized, single-center phase II clinical trial evaluates the effectiveness of early prophylactic radiotherapy in reducing the incidence of SREs. Eligible patients with metastatic solid cancers and up to five high-risk asymptomatic or minimally symptomatic bone metastases will be randomized in a 1:1 ratio into two groups. The control group will receive standard of care systemic therapy or observation according to tumor type and clinical guidelines. The intervention group will receive prophylactic external-beam radiotherapy (25 Gy in 5 fractions) to selected high-risk bone metastases in addition to standard of care.

Patients will be followed from baseline up to 12 months, with assessments conducted at predefined intervals. Study outcomes include the incidence of SREs, adverse events (graded according to CTCAE), patient-reported outcomes using validated questionnaires (EORTC QLQ-C30, EQ-5D-5L, BPI), economic burden, pain-free survival, and overall survival.

This study aims to determine whether early radiotherapy intervention can prevent skeletal complications, reduce healthcare burden, and improve patient outcomes in metastatic bone disease.

03

Conditions studied

  • Bone Metastases
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • prophylactic radiotherapy
  • early radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • confirmed solid
  • disease confirmed by imaging (CT, MRI, or PET-CT)
  • Presence of up to five high-risk bone metastases
  • High-risk bone metastases defined according to protocol criteria
  • Asymptomatic or minimally symptomatic bone metastases (not requiring opioid analgesics)
  • performance status 0-2
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy to the index bone preventing safe treatment planning
  • Symptomatic bone metastases requiring immediate palliative radiotherapy
  • Evidence of spinal cord compression
  • Bone metastases causing significant pain requiring opioid analgesics
  • Oligometastatic disease suitable for radical treatment
  • performance status ≥3
  • less than 3 months
  • Any condition that, in the investigator's opinion, would interfere with study participation or assessment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Prophylactic Radiotherapy + Standard of Care

    Participants receive prophylactic external-beam radiotherapy (25 Gy in 5 fractions) to up to five high-risk asymptomatic or minimally symptomatic bone metastases, in addition to standard of care systemic therapy or observation.

    Radiation: Prophylactic External Beam Radiotherapy · Other: Standard of Care

  • Active comparator
    Standard of Care

    Participants receive standard of care systemic therapy or observation according to tumor type and clinical guidelines, without prophylactic radiotherapy.

    Other: Standard of Care

Interventions

  • RadiationProphylactic External Beam Radiotherapy

    External beam radiotherapy delivered to up to five high-risk asymptomatic or minimally symptomatic bone metastases at a total dose of 25 Gy in 5 fractions.

  • OtherStandard of Care

    Systemic therapy or observation according to tumor type and clinical guidelines.

06

What researchers measure

Primary outcomes

  1. 1-year rate of skeletal-related events (SREs)

    Number of participants experiencing at least one skeletal-related event (pathological fracture, spinal cord compression, need for radiation to bone, need for surgery to bone, or tumor-related hypercalcemia) within 12 months after randomization.

    Time frame: From randomization to 12 months after randomization

Secondary outcomes

  1. Incidence of adverse events

    Adverse events assessed and graded according to CTCAE version 6.0

    Time frame: Up to 12 months after randomization

  2. EORTC QLQ-C30 global health status score

    EORTC QLQ-C30 global health status score at each assessment time point (range: 0-100; higher scores indicate better quality of life).

    Time frame: Baseline, 3 months, 6 months, and 12 months after randomization

  3. EQ-5D-5L index score

    EQ-5D-5L index score at each assessment time point (range typically from \<0 to 1; higher values indicate better health status).

    Time frame: Baseline and follow-up visits up to 12 months after randomization

  4. Brief Pain Inventory (BPI) pain intensity score

    Pain intensity score measured using the Brief Pain Inventory (scale 0-10; higher scores indicate worse pain).

    Time frame: Baseline and follow-up visits up to 12 months after randomization

  5. Pain-free survival

    Time from randomization to first occurrence of pain requiring opioid analgesics or death from any cause, whichever occurs first.

    Time frame: From randomization to 12 months after randomization

  6. Overall survival

    Time from randomization to death from any cause.

    Time frame: From randomization to 12 months after randomization

  7. Healthcare resource utilization

    Number and duration of hospitalizations, number of outpatient visits, and associated healthcare costs during the study period.

    Time frame: From randomization to 12 months after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Feb 2029, 32 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 32 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Jun 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 20, 2026
StartActual
Jun 2, 2026was Apr 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
Institute of Oncology Ljubljana is now Recruiting
Oct 9, 2026
Start date
Apr 2026→Jun 2, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    Institute of Oncology Ljubljana is now Recruiting
    Start date Apr 2026→Jun 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07540650
Lead sponsor
Institute of Oncology Ljubljana
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Jun 2, 2026
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Eva Ćirić, MD
Contact
eciric@onko-i.si
+38615879623
Klavdija Korošec
Contact
kkorosec@onko-i.si
+38631630065

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion